CARLMEDIUM SIGNALFINANCIAL10-Q

CARL's operating cash flow burn accelerated 59.5% to -$13.0M despite 25.2% gross profit growth, indicating scaling challenges in the AI-enabled spine surgery market.

The company is experiencing the classic growth-stage dilemma where revenue expansion isn't translating to improved cash efficiency, with operating cash burn worsening significantly quarter-over-quarter. While gross profit growth of 25.2% demonstrates market traction for their aprevo Technology Platform, the accelerating cash burn coupled with declining cash reserves suggests investors should monitor runway and path to profitability closely.

Comparing 2026-05-05 vs 2025-11-06View on EDGAR →
FINANCIAL ANALYSIS

CARL shows mixed financial signals with strong top-line momentum evidenced by 25.2% gross profit growth and increased R&D investment (+16.5%), but operational efficiency deteriorated sharply with operating cash flow burn accelerating 59.5% to -$13.0M. The company reduced total liabilities by 15.1% and maintained a solid cash position of $73.0M despite the $12.8M quarterly cash decline, suggesting adequate near-term liquidity but heightened focus needed on cash management. The overall picture reflects a growing medical technology company investing heavily for expansion but facing execution challenges in converting revenue growth to cash flow improvement.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-59.5%
-$8.2M-$13.0M

Operating cash flow fell 59.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-32%
$14.3M$9.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
+25.2%
$9.9M$12.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

R&D Expense
P&L
+16.5%
$4.4M$5.2M

R&D investment increased 16.5% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
-15.1%
$31.3M$26.5M

Liabilities reduced 15.1% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-14.9%
$85.8M$73.0M

Cash decreased 14.9% — monitor burn rate and upcoming capital needs.

Inventory
Balance Sheet
+11.8%
$1.8M$2.1M

Inventory built 11.8% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-05-05
PRIOR — 2025-11-06
ADDED
Financial Statements (Unaudited) 1 Condensed Balance Sheets as of March 31, 2026 and December 31, 2025 1 Condensed Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026 and 2025 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Three Months Ended March 31, 2026 and 2025 3 Condensed Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 4 Notes to Condensed Financial Statements 6 Item 2.
Our use or display of third parties trademarks, service marks, trade names, or products in this Quarterly Report on Form 10-Q is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us.
(the Company ) is a medical technology company pioneering artificial intelligence ("AI")-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
The Company designs, manufactures, and markets the aprevo Technology Platform for spine fusion surgery procedures that are performed at hospitals and ambulatory surgical centers.
This platform (the aprevo Technology Platform ) includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting patient-specific implants for spine surgery.
+7 more — sign up free →
REMOVED
Financial Statements (Unaudited) 1 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2025 and 2024 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Notes to Condensed Financial Statements 7 Item 2.
Our use or display of third parties trademarks, service marks, trade names, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us.
(the Company ) is a commercial-stage company within the surgical device with enabling technology sector.
The Company designs, manufactures, and markets aprevo , a comprehensive technology platform for spine fusion surgery procedures.
The aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.
+7 more — sign up free →
SIGNAL HISTORY — CARL
2025-11
2026-05
HighMediumLow
MORE FINANCIAL SIGNALS
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
CRMHIGHSalesforce delivered exceptional 291% revenue growth while simultaneously execut...
2026-03-02
TMOHIGHTMO reported extraordinary 309% revenue growth to $20.9B, likely driven by a maj...
2026-02-26
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →
MORE CARL SIGNALS
HIGHCARL completed a successful IPO in July 2025, dramatically improving its balance sheet wit...
2025-11-06